Catalog No.
DHD17218
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P16410
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
GIGA-564, GIGA 564, GIGA564
Clone ID
GIGA-564
Note
For research use only. Not suitable for clinical or therapeutic use.
ELISA assay for the quantification of ipilimumab in human serum, plasma, milk, and cerebrospinal fluid., PMID:38701533
A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer., PMID:38706247
Management of Autoimmune Encephalitis in a 7-Year-Old Child With CTLA-4 Haploinsufficiency and AMPA Receptor Antibodies: A Case Report., PMID:38728609
A Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and CTLA4-Mediated Immune Dysregulation Syndrome in Greece., PMID:38792965
Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?, PMID:38799429
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4., PMID:38806619
Immunotherapy for esophageal cancer: Where are we now and where can we go., PMID:38817664
Investigation of the Status of Immune Checkpoint Molecules in Meningiomas by Immunohistochemistry., PMID:38874241
Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer., PMID:38956700
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas., PMID:39028616
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort., PMID:39067873
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer., PMID:39068460
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy., PMID:39083809
Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy., PMID:39089739
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)., PMID:39097413
Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs., PMID:39123089
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab., PMID:39142718
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells., PMID:39214097
A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody., PMID:39226691
Revolutionizing Skin Cancer Treatment: The Rise of PD-1/PDL-1 and CTLA-4 as Key Therapeutic Targets., PMID:39257156
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors., PMID:39343510
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial., PMID:39366752
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors., PMID:39385035
The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study., PMID:39390972
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma., PMID:39406392
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer., PMID:39417692
Oral Lichenoid lesions induced by programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 bispecific antibody: a case report., PMID:39425127
JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune-Related Colitis Triggered by CTLA-4 and PD-1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report., PMID:39467776
Second-line monotherapy with a PD-1/CTLA-4 inhibitor effectively treated multiple brain and lung metastases of cervical cancer: a case report., PMID:39469707
CTLA-4 expressing innate lymphoid cells modulate mucosal homeostasis in a microbiota dependent manner., PMID:39496592
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers., PMID:39561273
Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020-2024)., PMID:39653621
Abatacept Induces Long-Term Reconstitution of the B-Cell Niche in a Patient With CTLA-4 Haploinsufficiency: A Case Report., PMID:39689284
Case report: Complete response in TMB-H advanced uterine clear cell carcinoma: a case analysis of paclitaxel albumin-bound combined with PD-1/CTLA-4 bispecific antibody., PMID:39776912
Integrating CTLA-4/PD-1 blockade into cervical cancer management: Results of COMPASSION-16., PMID:39798550
Engineered ipilimumab variants that bind human and mouse CTLA-4., PMID:39849917
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial., PMID:39920148
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer., PMID:39948608
pH-dependent dissociation from CTLA-4 in early endosomes improves both safety and antitumor activity of anti-CTLA-4 antibodies., PMID:39964714
High Antigenicity for Treg Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in Treg Cells., PMID:40017103
Combination of cadonilimab (PD-1/CTLA-4 bispecific antibody) and apatinib as salvage therapy achieves partial response in MSI-H advanced gastric cancer: a case report., PMID:40040691
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab-bevacizumab resistance and worse survival in advanced hepatocarcinoma., PMID:40048814
Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial., PMID:40069710
Reactivation of CTLA4-expressing T cells accelerates resolution of lung fibrosis in a humanized mouse model., PMID:40100323
Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study., PMID:40108113
Bispecific antibodies (bsAbs) directed against PD-1/PD-L1 and CTLA-4; a mini review., PMID:40112316
Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade., PMID:40248956
CTLA4 modulates B cell receptor signals to inhibit HBsAb secretion in chronic hepatitis B patients., PMID:40279930
Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study., PMID:40293533
Mathematical Modelling and Optimization of Medication Regimens for Combination Immunotherapy of Breast Cancer., PMID:40455115
For research use only. Not for human or drug use.
